CClinicalTrials.gg
Status unknownNCT04037982Updated Jul 30, 2019

RCT Study on Safety of LPD and OPD in the Treatment of Periampullary Tumors

An interventional study of laparoscopic pancreaticoduodenectomy and Open pancreaticoduodenectomy in Periampullary Tumor, Complication and Death, sponsored by Beijing Friendship Hospital. Status unknown at 1 site in China. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-30.

Sponsored by Beijing Friendship Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

Pancreaticoduodenectomy (PD) is considered one of the most complex and dangerous procedures in general surgery. This procedure is the preferred surgical procedure for treating tumors around the ampulla. Traditional open pancreaticoduodenectomy (OPD) has brought great surgical trauma to patients while treating diseases. In 1994, Gagner et al first reported laparoscopic pancreaticoduodenectomy (LPD). With the development of laparoscopic techniques, the updating of devices, and the continuous accumulation of laparoscopic gastrointestinal surgery experience, the results of retrospective studies published show that there is no significant difference in safety between LPD and OPD. However, the results of the recently published RCT study show that the mortality associated with LPD complications is five times greater than that of OPD. At present, the security of LPD has been controversial. Therefore we conducted a prospective randomized controlled trial with a primary outcome of perioperative complications, providing evidence-based results for the safe and effective clinical development of LPD.

02

Conditions studied

  • Periampullary Tumor
  • Complication
  • Death
  • Survival
03

In context

Lead sponsor

Beijing Friendship Hospital is the lead sponsor of 216 studies on the registry; 95 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Preoperative imaging diagnosis of periampullary tumor, or preoperative pathological diagnosis of periampullary tumor, preoperative evaluation can be performed pancreaticoduodenectomy; Serum bilirubin was less than 100 μ mol/L before operation; Sign a written informed consent form and agree to be randomly divided into groups for surgical treatment.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    LPD

    In this group, patients will undergo laparoscopic pancreaticoduodenectomy.

    Procedure: laparoscopic pancreaticoduodenectomy

  • Active comparator
    OPD

    In this group, patients will undergo open pancreaticoduodenectomy.

    Procedure: Open pancreaticoduodenectomy

Interventions

  • Procedurelaparoscopic pancreaticoduodenectomy

    During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.

  • ProcedureOpen pancreaticoduodenectomy

    During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.

06

What researchers measure

Primary outcomes

  1. Incidence of complications

    The patients number with complications / The total number in this group

    Time frame: 30 days after operation

07

Study locations

1 site
  • Beijing Friendship Hospital, Capital medical University
    Beijing, China
    • Wei Guo · Contact
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04037982
Lead sponsor
Beijing Friendship Hospital
Responsible party
Zhongtao Zhang (Chief Physician, Beijing Friendship Hospital) — Principal investigator
First posted
Jul 30, 2019
Start date
Aug 2019 (estimated)
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jul 30, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion